Defining a Standard Set of Patient-Reported Outcomes for Patients With Advanced Ovarian Cancer.

ABSTRACT

Purpose: Advanced ovarian cancer (AOC) and its treatment cause several symptoms and impact on patients' health-related quality of life (HRQoL). We aim to reach a consensus on the most relevant patient-reported outcome (PROs), the corresponding measures (PROMs), and measurement frequency during AOC patients' follow-up from patients' and healthcare professionals' (HCP) perspective. Methods: The project comprised five steps: 1) a literature review, 2) a focus group with patients, 3) a nominal group with HCP, 4) two round-Delphi consultations with patients and HCP, and 5) a final meeting with HCP. Delphi questionnaire was elaborated based on literature review, focus group (n=5 patients), and nominal group (n=16 HCP). The relevance of each PRO and the appropriateness (A) and feasibility (F) of the proposed PROM were assessed (Likert scale 1=strongly agree; 9=strongly disagree). The consensus was reached when at least 75% of the panelists rated it as 'relevant', 'appropriate', or 'feasible' (score 7-9). Results: A total of 56 HCP [51.8% Hospital Pharmacy; 41.1% Oncology; 3.6% Nursing; and 3.6% Psycho-oncology; mean time in specialty 12.5 (8.0) years] and 10 AOC patients [mean time diagnosis 5.4 (3.0) years] participated in the 1st round. All PROs achieved consensus regarding their relevance, except dry skin (58.0%). Agreement was reached for PRO-CTCAE to be used to assess fatigue (A84.9%; F75.8%), neuropathy (A92.4%; F77.3%), diarrhea (A87.9%; F88.7%), constipation (A86.4%; F75.8%), nausea (A89.4%; F75.8%), insomnia (A81.8%; F88.7%), abdominal bloating (A82.2%; F82.2%) and sexuality (A78.8%; F88.6%); EQ-5D to determine patients' HRQoL (A87.9%; F80.3%), pain (A87.9%; F75.8%) and mood (A77.7%; F85.5%); to assess treatment adherence the Morisky-Green (A90.9%; F84.9%) and the dispensing register (A80.3%; F80.3%) were chosen. It was agreed to note in the medical record whether the patient's treatment preferences had been considered during decision-making (A78.8%; F78.8%) and to use a 5-point Likert scale to assess treatment satisfaction (A86.4%; F86.4%). Panelists agreed (A92.4%; F 77.3%) to collect these PROs (1) at the time of diagnosis/relapse; (2) one month after starting treatment/change therapeutic strategy; (3) every three months during the 1st-year of treatment; and later (4) every six months until treatment completion/change. Conclusions: The consensus reached represents the first step towards including the patient's perspective in AOC follow-up. The standardized collection of PROs in clinical practice may contribute to optimizing the follow-up of these patients and thus improving the quality of care.